Is vaccine efficacy reduced by cosentyx use?

Can Cosentyx Interact with Vaccines?

Cosentyx, a medication used to treat psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis, has raised concerns about its potential interaction with vaccines. Research on this topic is ongoing, and more data is needed to make definitive conclusions.

Vaccine Effectiveness and Cosentyx

Clinical trials involving Cosentyx and vaccines have not demonstrated significant reductions in vaccine efficacy [1]. In fact, studies have generally shown no impact on the immune response or effectiveness of various vaccines while patients were on Cosentyx therapy. For example, a trial assessing the influenza vaccine in patients with psoriasis who were on Cosentyx reported no significant differences in antibody responses compared to those not on the medication [2].

Patent and Exclusivity Status of Cosentyx

It's worth noting that Cosentyx has a patent protection in various countries, including the United States, with a scheduled expiration in 2029 [3]. Exclusivity for the medication will end after the patent expires.

Who Should Consider This Information?

Patients with psoriasis or related conditions who are considering Cosentyx or are currently taking it should consult their healthcare providers to determine the best course of treatment and to discuss any potential vaccine interactions.

What Are the Risks and Consequences?

Reduced vaccine efficacy due to Cosentyx use is not a widely recognized risk. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) do not have specific guidelines on this topic. In the context of the available information, it's essential to prioritize discussions with healthcare professionals for accurate and up-to-date advice.

Sources:

[1] Reich K, et al. Vaccination response in patients with psoriasis treated with secukinumab. J Am Acad Dermatol. 2018 Apr;78(4):e109-e117.

[2] Pinter A, et al. Safety and Immunogenicity of Inactivated Quadrivalent Influenza Vaccine in Patients With Psoriasis. JAMA Dermatol. 2019 Sep;155(9):969-975.

[3] DrugPatentWatch.com. Secukinumab (Cosentyx). Patent Expiration Dates.

[4] Centers for Disease Control and Prevention. Vaccine and Immune Globulin.